Meeting highlights: International consensus panel on the treatment of primary breast cancer

被引：523

作者：

Goldhirsch, A

Glick, JH

Gelber, RD

Coates, AS

Senn, HJ

机构：

[1] Oncol Inst So Switzerland, Int Breast Canc Study Grp, Lugano, Switzerland

[2] Zentrum Tumordiagnost & Pravent, St Gallen, Switzerland

[3] European Inst Oncol, Int Breast Canc Study Grp, I-20141 Milan, Italy

[4] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA

[5] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA

[6] Australian Canc Soc, E Sydney, Australia

[7] Univ Sydney, E Sydney, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2001年 / 19卷 / 18期

关键词：

D O I：

10.1200/JCO.2001.19.18.3817

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：3817 / 3827

页数：11

共 85 条

[1]

Abe O, 1998, LANCET, V352, P930

[2]

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors:: 5-year follow-up results of French adjuvant study group 05 randomized trial [J].

Adenis, A ;

Bonneterre, J ;

Bonneterre, ME ;

Pion, JM ;

Vanlemmens, L ;

Gladieff, L ;

de Lafontan, B ;

Martel, P ;

Mihura, J ;

Roché, H ;

Gédouin, D ;

Kerbrat, P ;

Lesimple, T ;

Brémond, A ;

Devaux, Y ;

Delecroix, V ;

Fumoleau, P ;

Maugard-Louboutin, C ;

Namer, M ;

Goudier, MJ ;

Morice, F ;

Montcuquet, P ;

Schraub, S ;

Coudert, B ;

Fargeot, P ;

de Gislain, C ;

Mayer, F ;

Bastit, P ;

Chevallier, B ;

Grandgirard, A ;

Monnier, A ;

Sun, X ;

Clavère, P ;

Ollivier, JP ;

Rhein, B ;

Roullet, B ;

Datchary, J ;

Audhuy, B ;

Barats, JC ;

Kohser, F ;

Dides, S ;

Ramos, R ;

Cattan, A ;

Eymard, JC ;

Pourny, C ;

Weber, B ;

de Laroche, G ;

Pichon, A ;

Seffert, P ;

Hayat, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :602-611

[3]

[Anonymous], 1996, Lancet, V348, P1189

[4]

[Anonymous], 1988, NEW ENGL J MED, V319, P1681

[5]

[Anonymous], P ASCO

[6]

Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen [J].

Bentrem, DJ ;

Dardes, RC ;

Liu, H ;

Maccgregor-Schafer, J ;

Zapf, JW ;

Jordan, VC .

ENDOCRINOLOGY, 2001, 142 (02) :838-846

[7]

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer:: a randomised trial [J].

Bergh, J ;

Wiklund, T ;

Erikstein, B ;

Lidbrink, E ;

Lindman, H ;

Malmström, P ;

Kellokumpu-Lehtinen, P ;

Bengtsson, NO ;

Söderlund, G ;

Anker, G ;

Wist, E ;

Ottosson, S ;

Salminen, E ;

Ljungman, P ;

Holte, H ;

Nilsson, J ;

Blomqvist, C ;

Wilking, N .

LANCET, 2000, 356 (9239) :1384-1391

[8]

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial [J].

Boccardo, F ;

Rubagotti, A ;

Amoroso, D ;

Mesiti, M ;

Romeo, D ;

Sismondi, P ;

Giai, M ;

Genta, F ;

Pacini, P ;

Distante, V ;

Bolognesi, A ;

Aldrighetii, D ;

Farris, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2718-2727

[9]

BOCCARDO F, 2000, P AN M AM SOC CLIN, V19, pA71

[10]

CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J].

BONADONNA, G ;

VALAGUSSA, P ;

MOLITERNI, A ;

ZAMBETTI, M ;

BRAMBILLA, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :901-906

← 1 2 3 4 5 6 7 8 9 →